ANTIMICROBIAL AGENTS CHEMOTHERAPY, Nov. 2006, p. 3665â€“3673                                                                                      Vol. 50,  11
0066-4804/06/$08.00â«¹0 doi:10.1128/AAC.00555-06
Copyright Â© 2006, American Society Microbiology. Rights Reserved.



 Peptide Deformylase Inhibitors Potent Antimycobacterial AgentsäŒ¤â€ 
   Jeanette W. P. Teo,1â€¡ Pamela Thayalan,1 David Beer,1 Amelia S. L. Yap,1 Mahesh Nanjundappa,1
        Xinyi Ngew,1 Jeyaraj Duraiswamy,1 Sarah Liung,1 Veronique Dartois,1 Mark Schreiber,1
           Samiul Hasan,1 Michael Cynamon,2 Neil S. Ryder,3 Xia Yang,3 Beat Weidmann,3
                     Kathryn Bracken,3 Thomas Dick,1 Kakoli Mukherjee1*
       Novartis Institute Tropical Diseases, 10 Biopolis Road, 05-01 Chromos, Singapore 138670, Republic Singapore1;
        Central New York Research Corporation, New York, New York2; Novartis Institutes Biomedical Research,
                       , Infectious Disease Area, 100 Technology Square, Cambridge, Massachusetts 021393
                             Received 4 2006/Returned modification 6 June 2006/Accepted 17 August 2006

             Peptide deformylase (PDF) catalyzes hydrolytic removal N-terminal formyl group nascent
          proteins. essential step bacterial protein synthesis, making PDF attractive target anti-
          bacterial drug development. Essentiality def gene, encoding PDF Mycobacterium tuberculosis,           demonstrated genetic knockout experiments Mycobacterium bovis BCG. PDF M. tuberculosis
          strain H37Rv cloned, expressed, purified N-terminal histidine-tagged recombinant protein           Escherichia coli. novel class PDF inhibitors (PDF , N-alkyl urea hydroxamic acids, synthesized
          evaluated activities M. tuberculosis PDF enzyme antimycobacterial
          effects. compounds new class 50  inhibitory concentration (IC50) values <100 nM.
          PDF displayed antibacterial activity M. tuberculosis, including MDR strains MIC90
          values <1 â?®M. Pharmacokinetic studies potential leads showed compounds orally bio-
          available. Spontaneous resistance inhibitors arose frequency <5 â´› 10â´š7 M. bovis BCG.
          DNA sequence analysis spontaneous PDF resistant mutants revealed half mutants           acquired point mutations formyl methyltransferase gene (fmt), formylated Met-tRNA.           results study validate M. tuberculosis PDF drug target suggest class compounds
          potential developed novel antimycobacterial agents.


   Mycobacterium tuberculosis, pathogen causing 2 million                       active bacterial PDF challenge (51). far, Ni2â«¹,
deaths 8 million new cases tuberculosis (TB) year,                    Co2â«¹, Mn2â«¹ described cations stably leading health threat. fueled human                   replace Feâ«¹2 retaining high enzymatic activity (25, 49).
immunodeficiency virus epidemic appearance mul-                          Naturally occurring antibiotics, like actinonin, inhibit tidrug-resistant TB (17, 18, 46). Infections involving multidrug-                 activity PDF enzyme (2). Based structural (7, 39, 41)
resistant TB harder treat limited efficacy                 mechanistic design, high-throughput screening,
TB control programs (29). necessitated search                    classes PDF inhibitors (PDF  studied
new antituberculosis drugs novel mode action.                           previously (64). far, compounds having hydroxamic
   prokaryotes certain organelles, like plastids mi-                acid-chelating N-formyl hydroxylamine-chelating groups
tochondria eukaryotes, nascent proteins carry N-formylated                  potent enzyme inhibition, good antibacterial activity,
methionine (40). translational initiation, peptide defor-                   vivo efficacy, including oral activity (9, 12, 27).
mylase (PDF) (EC 3.5.1.27) removes N-formyl group                          work, validate def (gene encoding PDF) drug nascent proteins (42). Deformylated proteins undergo fur-                     target TB proving essentiality Mycobacterium bovis
ther N-terminal processing mature proteins (61). PDF                      BCG. PDF M. tuberculosis strain H37Rv cloned attractive candidate discovery antibacterial                     expressed heterologously E. coli. Recombinant tagged
agents, essentiality gene (def) encoding PDF                    M. tuberculosis PDF enzyme purified, biochemical shown Escherichia coli Streptococcus pneumoniae                      characterization carried  Activities novel class (8, 36). enzyme characterized highly unsta-                     PDF  N-alkyl urea reverse hydroxamates (27), 
ble metallopeptidase uses Fe2â«¹ catalytic metal (51).                  termined M. tuberculosis PDF enzyme cell-based
Oxidation Fe2â«¹ inactivates enzyme, purification                     assays antimycobacterial activity. potent lead, PDF-611
                                                                                  (LBK-611) (15), identified novel antimycobacterial
                                                                                  agent.
   * Corresponding author. Mailing address: Novartis Institute Trop-
ical Diseases, 10 Biopolis Road, 05-01 Chromos, Singapore 138670, 
                                                                                                           MATERIALS METHODS
public Singapore. Phone: 65-67222923. Fax: 65-67222917. E-mail:
kakoli.mukherjee@novartis.com.                                                      Enzymes, chemicals, antibiotics. Chemicals used highest
   â€¡ Present address: National University Hospital, Department                 grade commercially available. Chemicals antibiotics purchased Laboratory Medicine, 5 Lower Kent Ridge Road, Main Building,                      Sigma (St. Louis, Mo.), unless indicated. Restriction enzymes Level 3, Singapore 119 074, Republic Singapore.                                modifying enzymes purchased New England Biolabs,  (Beverly,
   â€  Supplemental material article http://aac            Mass.), used according manufacturerâ€™s recommendations.
.asm.org/.                                                                          Bacterial strains, plasmids, media. Bacterial strains plasmids used    äŒ¤
     Published ahead print 11 September 2006.                               study listed Table 1. E. coli strains cultured Luria-Bertani (LB)

                                                                           3665
 3666       TEO ET AL.                                                                                                            ANTIMICROB. AGENTS CHEMOTHER.

                                                        TABLE 1. Strains plasmids used work
  Strain plasmid                                                       Relevant characteristic(s)                                                  Source reference

Strains
  E. coli
     XL1-Blue                     recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac å…³Fâ¬˜ proAB lacIqZâŒ¬M15 Tn10 (Tetr)å…´;                                     Stratagene
                                     cloning strain
       M15(pREP4)                 Nals Strs Rif s Thiâ«º Lacâ«º Araâ«¹ Galâ«¹ Mtlâ«º Fâ«º RecAâ«¹ Uvrâ«¹ Lonâ«¹; expression strain                                      QIAGEN
                                     PT5-regulated gene expression

  M. bovis BCG                    Pasteur strain ATCC 35734                                                                                               ATCC
   XO22                           Single-crossover strain; Sucs Hygr                                                                                      work
   XOdef                          Single-crossover strain XO22 carrying complementation plasmid pMV262-def                                                work


Plasmids
  pCR-XL-TOPO                     Ampr; TA-cloning vector longer PCR products                                                                         Invitrogen
  pCR2.1-TOPO                     Ampr; TA-cloning vector                                                                                                 Invitrogen
  pQE30                           Ampr; low-copy-number plasmid inducible T5 promoter production N-                                           QIAGEN
                                    terminal His6 tag translational fusion
  pCR2.1-PDF                      M. tuberculosis def gene cloned pCR2.1-TOPO vector                                                                   work
  pQE30-PDF                       M. tuberculosis def gene cloned BamHI site pQE30                                                                  work
  pYUB657                         Ampr, Hygr; sacB counterselectable marker, E. coli-Mycobacterium shuttle vector                                         47
  pYUB657-dimer                   DNA fragment containing frame def deletion cloned pYUB657 suicide vector                                       work
  pMV262                          E. coli-Mycobacterium shuttle plasmid, hsp60 promoter; Kanr ColE1 OriM                                                  62
  pMV262-def                      pMV262 containing def gene, expressed translational fusion                                    work
                                    amino acids hsp60




broth (Becton Dickinson, Franklin Lakes, NJ) LB agar plates supplemented             (QIAGEN, Valencia, CA). Southern blot analysis, DNA samples di- 100 â?®g/ml ampicillin 50 â?®g/ml kanamycin cloning             gested appropriate restriction enzyme fragments separated 1 
maintenance. Terrific broth (12 g tryptone, 24 g yeast extract, 4 ml glycerol, 2.3 g     agarose gel transferred Hybond-Nâ«¹ nylon membrane (Amersham).
potassium phosphate [monobasic], 9.4 g potassium phosphate [dibasic], pH 7.5,            Southern hybridization carried using enhanced chemiluminescence
water make 1 liter) used growth medium expression PDF           direct nucleic acid labeling detection systems (Amersham). E. coli.                                                                               Expression purification M. tuberculosis PDF. M. tuberculosis
    M. bovis BCG cultured Middlebrook 7H9 (catalog  271310; Difco)             H37Rv genomic DNA sequence (GenBank accession number NC_000962) broth supplemented 10  (vol/vol) albumin-dextrose saline (0.81  NaCl,               used design primers 5â¬˜-ATGGATCCATGGCAGTCGTACCCATCCG-3â¬˜
5  bovine serum albumin fraction V [Roche, Mannheim, Germany], 2                     5â¬˜-ATGGATCCGTGACCGAACGGGTCGGG-3â¬˜, BamHI sites
glucose), 0.2  glycerol, 0.05  Tween 80 Middlebrook 7H10 (catalog              (underlined) incorporated  native TAA stop codon M.  262710; Difco) agar plates supplemented 10  (vol/vol) oleic acid-               tuberculosis def gene included utilize vector-encoded stop codon,
albumin-dextrose-catalase enrichment (catalog  212240; BBL), 0.5  glycerol,           resulting fusion protein MRGSHHHHHHGS-M. tuberculosis PDF-GSAC 0.05  Tween 80. required, hygromycin B (Roche) used                  ELGTPGRPAAKLN, residues italics originating vector. PCR
concentration 50 â?®g/ml. Sucrose used 7H10 medium 4                    carried using high-fidelity Platinum PCR Supermix (Invitrogen, Carls-
concentration.                                                                           bad, CA) according manufacturerâ€™s protocol. PCR products initially
    Buffers. Lysis buffer composed 50 mM HEPES (pH 7.5), 5 mM NiSO4,              cloned pCR2.1-TOPO cloning vector (Invitrogen), generating plasmid
5 mM MgSO4, 10 â?®g/ml catalase, 0.25 mM Tris(2-carboxyethyl)phosphine hy-
                                                                                         pCR2.1-PDF;  def gene subcloned BamHI-linearized E.
drochloride, 10 â?®g/ml DNase  1 ml protease cocktail inhibitor, 1 mg/ml ly-
                                                                                         coli expression vector pQE30 (QIAGEN), generating plasmid pQE30-PDF (Ta-
sozyme, 1  Triton X-100. Buffer composed 50 mM NaH2PO4, 300
                                                                                         ble 1). pCR2.1-PDF pQE30-PDF sequenced. DNA sequences
mM NaCl, 10 mM imidazole, pH 8.0. Buffer II composed 50 mM
                                                                                         analyzed using software Vector NTI, version 7.0 (InforMax, Frederick,
NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0. Buffer III com-
                                                                                         MD). Amino acid sequence alignments prepared using CLUSTALW, ver-
posed 50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0. Gel
                                                                                         sion 1.83 (11). DNA manipulations performed standard condi-
filtration buffer composed 50 mM NaH2PO4, 1 M NaCl, 5  glycerol.
                                                                                         tions described previously (55).
    Construction BCG def suicide plasmid def complementation
                                                                                            E. coli M15(pREP4) cells carrying pQE30-PDF grown terrific broth
plasmid. Gene regions flanking def gene PCR amplified ligated
                                                                                         containing 50 â?®g/ml kanamycin 100 â?®g/ml ampicillin 37Â°C obtain DNA fragment def gene (636 bp) excluded frame (Fig. 1A). Primers BglF (5â¬˜-TGGTAAATAGAGATCTGTGTGCGA                            optical density 600 nm reached â¬ƒ0.5. culture induced 0.1 mM
CGTCATAGCCGAGTT-3â¬˜) NdeR (5â¬˜-TGTCTTTTCATATGTAATGGT                                   isopropyl-â?¤-D-thiogalactopyranoside (IPTG) incubated 37Â°C addi-
CTCGTGGCCGGGGC-3â¬˜) amplify 1,150-bp fragment upstream def (left                    tional 4 h. Cells  1 liter) harvested, cell pellet washed
fragment). Primers NdeFF (5â¬˜-GAAGTGTACATATGGGGCTGAGGAGGC                                 twice sterile phosphate-buffered saline suspended 20 ml lysis buffer.
GGGCAAT-3â¬˜) BglRR (5â¬˜-TTTAATTTTAGATCTGGCGGGCTTTGGC                                   cells lysed incubation ice 30 min, followed sonication. Cell
ATAGCG-3â¬˜) amplify 1,173-bp fragment downstream def (right fragment).              debris removed centrifugation 35,000 â«» g 4Â°C 15 min. Primers BglF/BglRR NdefR/NdeFF carry BglII NdeI restriction sites,               proteins supernatant precipitated adjustment 60  saturation
respectively, enabled left right fragments ligated cloned        ammonium sulfate. pellet dissolved 10 ml buffer added pCR-XL-TOPO (Table 1). dimer fragment cloned                  Ni-nitrilotriacetic acid (NTA) slurry (QIAGEN) batch purification suicide vector pYUB657 (47), generating def suicide plasmid pYUB657-                 metal affinity chromatography. resulting mixture incubated 1 h dimer (Table 1). def complementation vector constructed cloning           gentle shaking 4Â°C. slurry washed twice buffer II, bound
def gene BamHI site pMV262 (Table 1), generating pMV262-def.                 PDF eluted buffer III. Active fractions obtained Ni-NTA batch vector introduced def single-crossover strain allow chromo-           purification purified gel filtration using HiLoad Superdex 26/60
somal def deleted.                                                                 prep grade column (Amersham) equilibrated gel filtration
    Genomic DNA isolation Southern blot analysis. Genomic DNA M.                buffer. Elution buffer flow rate 1 ml/min. bovis BCG isolated using protocol described DNeasy tissue kit               active fractions pooled concentrated using Vivaspin 20 centrifugal
 VOL. 50, 2006                                                                              PDF INHIBITORS ANTIMYCOBACTERIALS                                  3667




  FIG. 1.   Arrangement def neighboring genes M. tuberculosis genome. PCR fragments generated construction defâŒ¬
suicide vector indicated solid arrows. Materials Methods details. genetic map drawn scale. (B) Southern analysis defâŒ¬ mutants. defâŒ¬ mutants (lanes 2 4) obtained single-crossover strain complemented, trans, def carried plasmid pMV262. Lane 1, wild-type BCG; lane 5, single-crossover strain; lane 6, single-crossover strain XOdef, harboring def gene plasmid pMV262-def; lane 7, plasmid pMV262-def; lane M, 1-kb DNA marker. Genomic DNA digested HindIII probed def.
Wild-type BCG yields 10.3-kb fragment, single-crossover strain yields 8.3-kb fragment. fragments seen complemented defâŒ¬ mutants, indicating chromosomal copy def gene deleted.


concentrator (Sartorius, Hanover, Germany). Glycerol added final            plates reincubated overnight 37Â°C. STR used reference
concentration 33  (vol/vol), enzyme stored frozen â«º80Â°C.          drug plate. MICs obtained quantifying fluorescence    PDF enzyme assay. PDF enzyme assay format based published           Alamar Blue, using excitation emission wavelengths 530 nm 590 nm,
method (12), assay carried final volume 50 â?®l black,     respectively. Values 150,000 relative fluorescence units considered 96  half-area plates (Corning Costar, Etobicoke, Ontario, Canada).         reflect growth.
reaction mixture contained 50 mM HEPES (pH 7.5) â¬ƒ30 ng E. coli-                 Frequency spontaneous resistant mutants. Log-phase BCG cultures 109
expressed M. tuberculosis PDF  reaction initiated adding        CFU/ml plated 7H10 plates containing drug 10â«» MIC N-formyl-methionine-alanine-serine (fMAS) substrate final concentration     drug-free media. Plates incubated 37Â°C approximately 6 weeks 2 mM (Bachem, Germany). reaction room temperature 2.5           colonies appeared. frequency spontaneous resistance calculated
min terminated adding 25 â?®l fluorescamine (0.02 mg/ml dioxane).        ratio number colonies grew drug-supplemented plates microplate incubated 5 min read fluorescence       drug-free plates.
Tecan Saffire plate reader using excitation wavelength 380 nm             Mutational analyses def fmt genes. def fmt genes PDF 
emission wavelength 470 nm.                                                      resistant BCG mutants analyzed sequence variation. def gene
   Biochemical characterization M. tuberculosis PDF. Biochemical character-      region amplified using primers Updef (5â¬˜-GGTCCCGGTCTTGGTCTGC
ization M. tuberculosis PDF performed using pure batch-purified          3â¬˜) Dndef (5â¬˜-CGGCGATGATGCCCGCCG-3â¬˜), generating 838-bp
recombinant enzyme. effect substrate concentrations M. tuberculosis       amplicon. primers Upfmt (5â¬˜-TAGCGTGCCTTGCGTACCCA-3â¬˜) PDF activity studied using N-formylated peptide substrates, N-formyl-       Dnfmt (5â¬˜-CAGCGCGGGCAACACCAG-3â¬˜) amplify 1,178-bp ampli-
methionine-alanine (fMA) fMAS (Bachem), concentrations ranging              High-fidelity PCR carried using Proof Start DNA polymerase 0 10 mM. effects divalent metal ions Ca2â«¹, Mg2â«¹, Mn2â«¹,           (QIAGEN). PCR products purified agarose gels using Co2â«¹, Cu2â«¹, Ni2â«¹, Zn2â«¹ PDF activity assessed addition         QIAquick gel extraction kit (QIAGEN). purified PCR products se-
different ions final concentration 1 mM assay buffer.                quenced Research Biolabs Technologies (Singapore). Jalview software    inhibition studies M. tuberculosis PDF, 30-min preincubation     used visualizing alignment (11), software used inhibitor enzyme included prior initiating reaction.        bioinformatics analysis secondary-structure prediction mutants (13).
concentrations inhibitors varied 0 10 â?®M. Fifty percent inhibitory      vivo pharmacokinetic studies. CD-1 female outbred mice (BioArc, India)
concentration (IC50) values obtained fitting data sigmoid dose-    used pharmacokinetic studies selected PDF inhibitors. intrave-
response equation using GraphPad Prism software, version 3.0 (GraphPad Soft-        nous  v.) oral (p.o.) administration, compounds formulated 4 
ware, , San Diego, CA).                                                         10  polyethylene glycol 300, respectively. 1 week acclimation, mice
   Antimicrobial agents drug susceptibility testing. Streptomycin (STR),        received dose 1 mg/kg body weight v. tail vein injection dose isoniazid (INH), rifampin (RIF), linezolid (LZD), erythromycin (ERY)            5 mg/kg p.o. gavage. Groups mice euthanized CO2 inhalation obtained Sigma (St. Louis, Mo.). Stock solutions STR, LZD,         different intervals 5 min 4 h following dosing. Blood samples ERY prepared 10 mM concentration deionized water, INH,             collected cardiac puncture heparinized tubes. Blood centrifuged, RIF, PDF dissolved 90  dimethyl sulfoxide. Drug susceptibility        plasma recovered stored frozen â«º80Â°C. Plasma samples ex-
testing based previously published method (20). Logarithmic-phase M.       tracted 1 ml ethyl acetate, analyzed, quantified drug content bovis BCG cultures diluted complete 7H9 broth obtain optical          liquid chromatography coupled triple quadrupole mass spectrometry (X-
density 600 nm â¬ƒ0.04, corresponded approximately 106 CFU/ml,         Terra, C18, 4.6 50 mm, 5 â?®m), carbamazepine internal standard. added test plate. plates incubated 37Â°C 4       quantitative calibration, standard curves established using spiked com-
days. fourth day, 50 â?®l freshly prepared 1:1 mixture Alamar Blue     pounds plasma. limit detection 10 ng/ml. noncompartmental
(Serotec , Oxford, United Kingdom) 10  Tween 80 added           model (WINNONLIN, version 4.1) used calculate pharmacokinetic pa-
 3668       TEO ET AL.                                                                                                 ANTIMICROB. AGENTS CHEMOTHER.




  FIG. 2. Expression M. tuberculosis PDF E. coli.   SDS-PAGE analysis PDF expressed E. coli M15(pREP4) carrying pQE30-PDF.
Lane 1, total cell protein uninduced; lane 2, total cell protein induced; lane 3, soluble fraction; lane 4, insoluble fraction; lane 5, Ni-NTA
batch-purified M. tuberculosis PDF; lane 6, M. tuberculosis PDF purified gel filtration; lane M, low-range molecular mass marker (Amersham).
Arrows indicate position recombinant tagged PDF. (B) Effects various substrate (fMA fMAS) concentrations recombinant
M. tuberculosis PDF activity. RFU, relative fluorescence units.



rameters. p.o. bioavailability calculated ratio area   confirmed contained def deletion chromo-
curve (AUC) p.o. administration AUC v. administration corrected       (Fig. 1B). mutants probed def, dose (F â«½ AUCp.o. â«» dosei.v./AUCi.v. â«» dosep.o.).
                                                                                       chromosomal copy def detected (Fig. 1B).
                                                                                           Expression purification M. tuberculosis PDF.                                   RESULTS                                              shown Fig. 2A, recombinant M. tuberculosis PDF ex-
   Essentiality def, gene encoding peptide deformylase                       pressed high levels E. coli.  expressed pro-
M. bovis BCG. order determine essentiality peptide                        tein largely insoluble form (Fig. 2A, lane 4). Insol-
deformylase M. bovis BCG, step allelic-exchange                               ubility recombinant M. tuberculosis PDF reported
methodology (47) employed generate def deletion mu-                             earlier (57). Despite low solubility M. tuberculosis PDF,
tants. suicide plasmid, pYUB657-dimer (Table 1), elec-                           purification E. coli extracts performed native
troporated BCG, single-crossover strain, XO22,                              conditions. enzyme purified homogeneity com-
confirmed Southern hybridization (Table 1; Fig. 1B),                            bination ammonium sulfate fractionation, Ni-NTA, gel
obtained. strain sucrose sensitivity hygromycin                         filtration chromatography. Typical yields 1.2 mg/liter. resistance (Sucs Hygr) phenotype conferred inte-                           resulting purified protein showed single band sodium
gration suicide vector chromosome.                           dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
second recombination event, selection markers elim-                           PAGE) gels (Fig. 2A, lane 6) showed enzymatic activity inated 75 revertant (Sucr Hygs) colonies screened                          N-formylmethionyl peptides.
PCR. positive chromosomal def. 28 colonies                                SDS-PAGE analysis (Fig. 2A, lane 6) showed hyg negative PCR analyzed Southern                                purified protein molecular mass â¬ƒ30 kDa. blotting probing def. Hybridization results showed                        slightly larger predicted molecular mass 23.96 recombinants retained wild-type def gene (3.8-kb                        kDa (inclusive His6 tag additional 17 amino
band), single-crossover strain second-                        acids C terminus introduced ary recombinants derived generated larger, 4.6-kb frag-                         vector). anomalous migration recombinant M. tu-
ment (data shown), suggesting def gene essential                       berculosis PDF observed earlier (57). Analytical gel deleted.                                                                 filtration HiLoad Superdex 26/60 prep grade column
   copy def cloned pMV262 (pMV262-def, Kanr [Ta-                             gave apparent molecular mass 24.5 kDa, close ble 1]) introduced single-crossover strain XO22,                          deduced amino acid sequence (23.96 kDa). resulting transformant XOdef (Table 1). Double crossovers                           suggested peptide deformylase enzyme behaved isolated XOdef culturing strain ab-                            monomeric species native conditions used sence hygromycin, allowing integrated vector se-                           purification. Identity 30-kDa protein 
quence lost. 28 Sucr Hygs Kmr colonies                            firmed Western blotting using anti-PDF antibody selected lost integrated suicide vector.  25                          anti antibody (data shown).
contained wild-type def gene chromosome (data                               significant loss protein enzyme activity
shown). Southern hybridization remaining isolates                         fractions obtained gel filtration suit-
 VOL. 50, 2006                                                                   PDF INHIBITORS ANTIMYCOBACTERIALS                3669


                         TABLE 2. Effects PDF M. tuberculosis PDF H. sapiens PDF enzyme activities
                                     (IC50s) antibacterial activities (MIC90s) M. bovis BCG
                                                                            IC50 (nM)
                                                                                                      MIC90 (â?®M)        Compound                      Structure                                                                              Reference(s)
                                                              M. tuberculosis           H. sapiens    M. bovis BCGa
                                                                  PDFa                    PDF



Actinonin                                                      50.5 â«¾ 7.7                  43            â¬Ž25                   12, 32




PDF-709                                                        90.0 â«¾ 4.2                 147a             6.25                27




                                                                                              PDF-611 (LBK-611)                                              69.5 â«¾ 0.7                 115              0.78                15




BB-3497                                                        23.9 â«¾ 7.5                    8             3.125               12, 45



      work.



able large-scale screens. Instead, reported earlier E.      lier reports indicated Co2â«¹, Ni2â«¹, Zn2â«¹ coli PDF (10), batch-purified M. tuberculosis PDF (Fig. 2A,             effect M. tuberculosis PDF enzyme activity (57).
lane 5) used screening large library.         Enzyme inhibition studies. inhibitors avail-
background (induced E. coli M15 cell extracts transformed               able PDF library (27) tested M. tuberculosis PDF pQE30 vector, treated similar way) sub-               enzyme assay (Table 2). active compound, PDF-611,
tracted, enzyme activity batch specific         LBK-611 (15), IC50 69.5 nM, similar completely inhibited PDF  hits recon-            compound, PDF-709, IC50 90 nM. known
firmed using purified enzyme.                                       antibacterial PDF  actinonin (10) BB-3497 (12, 14),
   Biochemical characterization E. coli-expressed M. tuber-          showed potent inhibition M. tuberculosis PDF enzyme,
culosis PDF. Biochemical characterization            IC50s 50.5 23.9 nM, respectively.
pure batch-purified enzyme, results               order assess issue selectivity, compounds
similar. optimization substrate concentrations             tested purified Homo sapiens PDF fMA fMAS, optimal                 human matrilysin (MMP-7). Matrilysin belongs ma-
substrate M. tuberculosis PDF (Fig. 2B). prominent fea-           trix metalloproteinase (MMP) family zinc-containing 
ture kinetics observed substrates tested       zymes related PDF (44). PDF-611 (LBK-611) PDF- enzyme showed saturation kinetics â¬ƒ10 mM                   709 inhibited H. sapiens PDF IC50s 115 nM 147
substrate, concentrations 12.5 mM fMAS                nM, respectively (Table 2). BB-3497 IC50 8 nM
hibitory M. tuberculosis PDF. finding similar           H. sapiens PDF (45) actinonin IC50 43 nM earlier report (57) (Fig. 2B). Subsequently, 2 mM          (32).  compounds displayed significant inhibi-
fMAS used evaluating parameters enzyme             tion MMP-7 concentrations 10 â?®M inhibited
assays. Velocity versus substrate concentration plots typically         growth K562 cell line concentrations 10
produced straight line, indicating Km values       â?®M, actinonin, IC50 8.5 â?®M (data
substrates â¬Ž5 mM (data shown).                                  shown).
   enzyme displayed pH optimum 7.5, retaining                Antimycobacterial activities PDF-611 (LBK-611) 20  optimal activity extreme pH, example,         PDF-709. PDF-611 (LBK-611) potent terms pH 5.5 pH 10 (data shown). Ionic strength sig-             antimycobacterial activity, MIC90 value 0.78 â?®M (0.25
nificant detrimental effect M. tuberculosis PDF activity          â?®g/ml) (Table 2). PDF-709 BB-3497 displayed good
concentrations greater 0.1 M KCl (data shown).            antimycobacterial activities growing M. bovis BCG cul-
result agreed earlier results M. tuberculosis PDF (57).       tures (MIC90s 6.25 â?®M 3.125 â?®M, respectively); 
Co2â«¹, Ni2â«¹, Zn2â«¹ partially inhibitory, Cu2â«¹               actinonin showed poor antimycobacterial effect, ions completely abolished PDF activity (data shown). Ear-           MIC90 â¬Ž25 â?®M (â¬Ž16 â?®g/ml). Based results obtained
 3670        TEO ET AL.                                                                                                     ANTIMICROB. AGENTS CHEMOTHER.


       TABLE 3. MICs PDF-611 (LBK-611) various                                          TABLE 4. Bioinformatics analysis fmt mutants
                    M. tuberculosis isolates
                                                                                                                                            Predicted                                                                                                       Mutation    Predicted structural
                                                   MIC (â?®g/ml)b                          Mutant                                              8 Ã… fMet-tRNA
                                                                                                        FMT               locationa
          Strain                                                                                                                                                   binding sitea
                                   PDF-611           BB-3497          Gatifloxacin
                                                                                        fmt-100         P100L              Loop                     H37Rv (ATCC 27294)              0.125â€“0.5          0.125â€“0.5           0.03â€“0.06        fmt-222a        E222K              Helix                    Beijing MDR                        0.125           0.125â€“0.25          0.03â€“0.06        fmt-53          A53V               Helix                    W-Beijing MDR                      0.125              0.125             0.25            fmt-32a         T32N               Loop                     Yes
Beijing F29 MDR                  0.03â€“0.25          0.03â€“0.5            0.015           fmt-32b         T32N               Loop                     Yes
Inhr SDR                         0.06â€“0.125           0.125             0.015           fmt-230         P230S              Loop                     Yes
Strr SDR                            0.5               1.0               0.03            fmt-105         V105F              Sheet                    Yes
Rifr SDR                            0.25              1.2               0.015           fmt-32c         T32N               Loop                     Yes
Pzar SDR                            0.5               1.0               0.03            fmt-192         R192P              Loop                     Clinical MDR                     0.06â€“1.0           0.06â€“2           â¬?0.008â€“0.06        fmt-276         T276A              Loop                                                                                                           fmt-104a        W104L              Loop                          MDR, multidrug resistance; SDR, single-drug resistance; Pza, pyrazinamide. clinical MDR isolates 10 clinical isolates described MDR;         fmt-104b        W104L              Loop                      detailed susceptibility pattern TB drugs available.               fmt-117a        G117C              Sheet                    Yes
   b
     MIC determinations twice. Single MIC values represent iden-          fmt-124         A124G              Helix                    Yes
tical values experiments, multiple values indicate different results   fmt-222b        E222K              Helix                    experiments. clinical MDR, multiple values indicate range            fmt-117b        G117C              Sheet                    Yes
MIC values 10 different clinical isolates.
                                                                                                                                                                                      Deduced model M. tuberculosis FMT, based E. coli FMT
                                                                                        crystal structure (59).
 M. tuberculosis PDF inhibition antimycobacterial
studies, compounds PDF-709 PDF-611 (LBK-611) selected analyses.                                                     formyl methyltransferase (FMT) mutants mutations
   bactericidal effects PDF-611 (LBK-611) PDF-                               mapped regions active site, deduced 709 M. bovis BCG 4 days determined                                 homology model M. tuberculosis FMT based E. coli FMT
time-kill studies (data shown). 1â«» 10â«» MIC                              crystal structure (Table 4; Fig. S3 supplemental compound, â¬?1 log unit decrease viable                             material).
counts, demonstrating bacteriostatic effect time pe-                             studies mutant strains, fmt-192, fmt-276, fmt-
riod tested.  increasing incubation time                            104a, fmt-104b characterized growth antimi-
inhibitor, higher bacterial killing observed                            crobial susceptibility, generated concentrations (data shown), indicating PDF                          PDF-709. isolates, fmt-192 fmt-104a, slower dou-
slow acting. PDF-611 (LBK-611) shown effective                           bling times (32 h 35 h, respectively) wild-type M. bovis clinical isolates M. tuberculosis. com-                          BCG (23 h), fmt-276 fmt-104b doubling times
pound demonstrated low MICs (â¬?1 â?®g/ml) multi-                               (22 h 24 h, respectively) similar wild-type M.
drug-resistant clinical TB isolates (Table 3).                                          bovis BCG (23 h). MIC testing, FMT mutants    Spontaneous mutation rates analysis PDF resis-                              16-fold increase MIC (â¬Ž100 â?®M)
tant M. bovis BCG isolates. frequency spontaneous                                PDF-611 (LBK-611) PDF-709.  resistance development evaluated using concentration                              mutants retained susceptibility TB drugs, like RIF 10â«» MIC. PDF-611- PDF-709-resistant mutants                                      STR, unrelated drugs, like LZD ERY. Target speci-
arose frequencies â±•5 â«» 10â«º7 M. bovis BCG.                                ficity confirmed expression extra chromo-
mutation frequencies lower development                                 somal copies M. tuberculosis def gene BCG, resulting
resistance INH, occurred frequency 7 â«»                                 16-fold increase MIC PDF-611 (LBK-611) (data
10â«º5, higher RIF, â¬ƒ1 â«» 10â«º8                                 shown). comparative purposes, mutant (data shown).                                                                       mutation def fmt gene included study.
   development PDF resistance bacteria                            mutant slightly slower doubling time (26 h) progress main mechanisms, mutations                             wild-type M. bovis BCG, susceptibility profile similar def gene mutations formyl methyltransferase gene                          fmt mutants. fmt mutants regained susceptibility
(fmt), catalyzes formylation methionylated initia-                         PDF wild-type fmt gene supplied trans,
tor tRNA (12, 21, 34, 35). spontaneous PDF                                confirming resistance arose mutation fmt
resistant M. bovis BCG mutants characterized. com-                             (data shown).
plete def fmt genes isolates sequenced.                                Pharmacokinetic studies mice. Clearance PDF-709 isolates mutations def gene. 29                           PDF-611 (LBK-611) mouse serum measured isolates, 16 missense mutations fmt                           compounds administered v. p.o. concentra-
gene (Table 4). remaining 13 isolates, changes                           tions serum different times used calculate detected def fmt genes. noted indepen-                           corresponding pharmacokinetic parameters presented Table
dently isolated mutants amino acid mutation                                5. PDF-611 (LBK-611) lower half-life (0.5 h) PDF-
(fmt-32a, fmt-32b, fmt-32c T32N mutation; fmt-                              709 (1.6 h) v. administration.  PDF-611 (LBK-
222a fmt-222b E222K mutation; fmt-117a                              611) higher half-life (3.7 h) PDF-709 (2.7 h) fmt-117b G117C mutation). Nonconserved amino acid                               p.o. administration. compounds similar bioavailabili-
changes observed half mutants. half                            ties (â¬ƒ40 ).
 VOL. 50, 2006                                                                           PDF INHIBITORS ANTIMYCOBACTERIALS                            3671


                              TABLE 5. Pharmacokinetic parametersa PDF-611 (LBK-611) PDF-709 mice
                             Type            Dose        Cmax                        AUCinf                       CL              Vss       Bioavailability
      Compound                                                          Tmax (h)                     t1/2 (h)
                           administration      (mg/kg)     (ng/ml)                    (ng Â· h/ml)                (ml/min/kg)     (liter/kg)        ( )

PDF-611(LBK-611)                v.           1.000        603.6        0.083          253.5        0.500           65.8           3.0
                                p.o.           5.000        194.3        0.250          566.0        3.70                                           45.0

PDF-709                         v.           1.000        902.0        0.083          145.6        1.600         114.5            3.9
                                p.o.           5.000        186.0        0.500          293.0        2.700                                          40.0
      Cmax, maximum concentration drug serum; Tmax, time maximum concentration drug serum; AUCinf, area curve extrapolated â¬?; t1/2,
half-life; CL, clearance; Vss, volume distribution steady state.




                             DISCUSSION                                            mutations residues important function  use                                                                                    homology model E. coli FMT crystal structure) (Table
   M. tuberculosis PDF earlier proposed potential drug                    4; Fig. S3 supplemental material) (23, 26, 59).
target (14) BB-3497, PDF inhibitor, potent vitro                    independently isolated mutants (fmt-32a, fmt-32b, activity M. tuberculosis. gene encoding M. tubercu-                    fmt-32c  T32N mutation]) Ser Ala mutation
losis PDF shown genes required
                                                                                   region involved recognition initiator tRNA optimal growth M. tuberculosis transposon site
                                                                                   (53, 54). Mutant fmt-53  A53V mutation) lies just
hybridization (56). work, failure obtain def dele-
                                                                                   outside region. mutants mutations tion mutants M. bovis BCG strongly suggested                                                                                    C-terminal region involved recognition tRNA deletion def lethal. second recombination
                                                                                   FMT obtained (fmt-222a, fmt-222b, fmt-230, fmt-
event, chromosomal wild-type def gene deleted
                                                                                   276) (23). mutants, fmt-104a fmt-104b  presence extra chromosomal complementing
                                                                                   W104L mutation) fmt-100  P100L mutation),
copy def. Taken  results def
                                                                                   mapping close conserved residues (Asn-106, 108, gene essential M. bovis BCG.
                                                                                   Asp-144) predicted participate catalytic steps (1,
   observed previously E. coli PDF                                                                                    28)  Fig. S3 supplemental material). 
metal ions reaction conditions (substrate type 
                                                                                   mylation assays Met-tRNAfMet, unsure say) dramatically change activity properties                                                                                    extent different fmt mutations affect transformylase
enzyme (10, 38, 49, 50). biochemical characterization
                                                                                   activity. studies needed understand func- M. tuberculosis PDF, observed differences earlier published work (57, 58). differences possi-                    tional effect mutations.
bly attributed difference assay protocol ex-                         Mutants did mutations def fmt
pression/purification conditions followed study com-                       gene efflux pump mutants, observed E. coli pared earlier published work. earlier work,                      Haemophilus influenzae (12, 15).  actual mecha-
investigators purified enzyme presence                       nism resistance mutants remains elucidated.
excess Niâ«¹2 enzyme activity determined using fMA                         case mycobacteria, mechanism substrate trinitrobenzenesulfonic acid assay (57).                        operative confer resistance PDF   assay temperatures different (room                            Recently, eukaryotic PDF enzymes iden-
temperature study versus 30Â°C previous study).                      tified characterized, e.g., Arabidopsis thaliana (22),
   Structure-activity relationship studies actinonin                  Plasmodium falciparum (5), mitochondria H. sapiens
N-alkyl urea hydroxamates (9, 27) indicate efficacious                        (22, 32, 33, 45, 60). mRNA H. sapiens PDF PDF share common structural features,                          shown expressed similar levels types human
metal-chelating group, usually hydroxamate/reverse hydrox-                       tissues (22), enzyme active deformylase amate, second n-alkyl butyl residue P1â¬˜                    vitro vivo (32, 33, 60). Actinonin position mimics methionine chain (4). PDF                      inhibit cell growth various human tumor cell lines tested work reverse hydroxamates, carrying                         tumor models (32, 33, 63). addition, characterized
n-butyl residue P1â¬˜ position (Table 2). class                       bacterial PDF inhibitors, BB-3497 actinonin  used compounds inhibit M. tuberculosis PDF IC50s â¬?100 nM                        study), inhibit H. sapiens PDF nanomolar concentra- bacteriostatic M. bovis BCG, observed                       tions similar bacterial counterpart 
previously PDF Staphylococcus aureus                      hibited (32, 45). E. coli (3, 12, 35). frequency resistance class                     despite inhibition cell-free H. sapiens inhibitors M. bovis BCG similar previously                    PDF antiproliferative effects tumor cell lines, num-
reported S. aureus (12, 35) E. coli (3, 12).                               ber normal cell lines resistant acti-
   Spontaneous PDF resistant isolates M. bovis BCG dem-                       nonin (33) BB-3497 (45). Actinonin tol-
onstrated elevated MICs specifically PDF                         erated mice doses 400 mg/kg (24), drug classes. work, resistance                        successors BB-3497 (BB-83698) tested hu-
arose missense mutations fmt gene 16                      mans levels 475 mg clinically signif-
29 mutants, rest mutation def                    icant adverse effects (52). Furthermore, recent biochemical fmt gene. fmt mutants study                      studies H. sapiens PDF showed enzyme  3672      TEO ET AL.                                                                                                       ANTIMICROB. AGENTS CHEMOTHER.


significantly lower activity (kcat/Km) bacterial                           Locher, M. G. Page, W. Pirson, G. Rosse, J. L. Specklin. 2000. Hydrox-
                                                                                       amic acid derivatives potent peptide deformylase inhibitors antibac-
zyme (E. coli PDF) (32, 33, 45, 52, 60).                                               terial agents. J. Med. Chem. 43:2324â€“2331.
   addition, unambiguous localization H. sapiens PDF                    3.   Apfel, C. M., H. Locher, S. Evers, B. Takacs, C. Hubschwerlen, W. Pirson, mitochondria important, evidence suggests                        M. G. Page, W. Keck. 2001. Peptide deformylase antibacterial drug
                                                                                       target: target validation resistance development. Antimicrob. Agents
mitochondria tumor cells sensitive mito-                             Chemother. 45:1058â€“1064.
chondrial insult (6, 48). examples drugs selectively                 4.   Boularot, , C. Giglione,  Artaud, T. Meinnel. 2004. Structure-activity
toxic cancer cells working inhibition mito-                          relationship analysis therapeutic potential peptide deformylase inhib-
                                                                                       itors. Curr. Opin. Investig. Drugs 5:809â€“822.
chondrial respiration (19, 43). Mitochondrial membranes                       5.   Bracchi-Ricard, V., K. T. Nguyen, Y. Zhou, P. T. Rajagopalan, D. permeable small molecules membranes                            Chakrabarti, D. Pei. 2001. Characterization eukaryotic peptide
                                                                                       deformylase Plasmodium falciparum. Arch. Biochem. Biophys. 396: act efficient supplementary filter drugs.                       162â€“170. reason, number antibiotics (tetracycline, macrolides,                   6.   Cavalli, L. R., B. C. Liang. 1998. Mutagenesis, tumorigenicity, ) inhibit mitochondrial targets (16, 30, 31, 37)                          apoptosis: mitochondria involved? Mutat. Res. 398:19â€“26.
                                                                                  7.   Chan, M. K., W. Gong, P. T. Rajagopalan, B. Hao, C. M. Tsai, D. Pei. currently used human medicine.  acti-                             1997. Crystal structure Escherichia coli peptide deformylase. Bio-
noninâ€™s inhibition H. sapiens PDF, resulting mitochon-                           chemistry 36:13904â€“13909.
drial disruption, similar tumor specificity (33).                  8.   Chan, P. F., K. M. Oâ€™Dwyer, L. M. Palmer, J. D. Ambrad, K.  Ingraham,
                                                                                       C.  M.  Lonetto, S. Biswas, M. Rosenberg, D. J. Holmes, M.
major, striking difference H. sapiens PDF  mouse                          Zalacain. 2003. Characterization novel fucose-regulated promoter
PDF) bacterial PDF (E. coli PDF) highly                              (PfcsK) suitable gene essentiality antibacterial mode action studies
                                                                                       Streptococcus pneumoniae. J. Bacteriol. 185:2051â€“2058.
served EGCLS motif (motif III), leucine mutated                                                                                   9.   Chen, D., C. Hackbarth,  J. Ni, C. Wu, W. Wang, R. Jain, Y.  K.
glutamic acid mammalian PDF (Glu-173 H. sapiens PDF),                            Bracken, B. Weidmann, D. V. Patel, J. Trias, R. J. White,  Yuan. 2004. results low activity H. sapiens PDF (60).                         Peptide deformylase inhibitors antibacterial agents: identification                                                                                        VRC3375, proline-3-alkylsuccinyl hydroxamate derivative, using  sequence similarity, M. tuberculosis PDF 11  identical                          tegrated combinatorial medicinal chemistry approach. Antimicrob.
overall 6  identity active site H.                            Agents Chemother. 48:250â€“261.
sapiens PDF. differences exploited make com-                     10.   Chen, D. , D. V. Patel, C. J. Hackbarth, W. Wang, G. Dreyer, D. C. Young,
                                                                                       P. S. Margolis, C. Wu,  J. Ni, J. Trias, R. J. White,  Yuan. 2000.
pounds decreased affinity H. sapiens PDF                              Actinonin, naturally occurring antibacterial agent, potent deformylase
affecting potency respect M. tuberculosis PDF.                        inhibitor. Biochemistry 39:1256â€“1262. study, PDF selectivity M. tuber-                  11.   Clamp, M., J. Cuff, S. M. Searle, G. J. Barton. 2004. Jalview Java
                                                                                       alignment editor. Bioinformatics 20:426â€“427.
culosis PDF, considered studies                    12.   Clements, J. M., R. P. Beckett,  Brown, G. Catlin, M. Lobell, S. Palan, W. tolerability mice, addition lack effect                    Thomas, M. Whittaker, S. Wood, S. Salama, P. J. Baker, H. F. Rodgers, V.
                                                                                       Barynin, D. W. Rice, M. G. Hunter. 2001. Antibiotic activity char-
MMP-7 K562 cell line 10 â?®M (â¬ƒ100-fold-higher                             acterization BB-3497, novel peptide deformylase inhibitor. Antimicrob.
concentration H. sapiens PDF IC50).                                               Agents Chemother. 45:563â€“570.
   order ensure treatment compliance, antituberculosis                     13.   Cuff, J. , G. J. Barton. 1999. Evaluation improvement multiple
                                                                                       sequence methods protein secondary structure prediction. Proteins 34:
therapy requires oral dosing regimen day                          508â€“519. oral bioavailabilities PDF-611 (LBK-611) PDF-709                      14.   Cynamon, M. H., E. Alvirez-Freites,  E. Yeo. 2004. BB-3497, peptide range 40  mouse, indicating potential                            deformylase inhibitor, active Mycobacterium tuberculosis. J. 
                                                                                       timicrob. Chemother. 53:403â€“405.
oral administration humans. reinforced                   15.   Dean, C. R., S. Narayan, D. M. Daigle, J. L. Dzink-Fox, X. Puyang, K. R.
relatively long half-lives 3.7 h 2.7 h, respectively, fol-                      Bracken, K. E. Dean, B. Weidmann,  Yuan, R. Jain, N. S. Ryder. 2005.
                                                                                       Role AcrAB-TolC efflux pump determining susceptibility Hae-
lowing oral administration. Assuming interspecies scaling                              mophilus influenzae novel peptide deformylase inhibitor LBM415. normal range, half-life mouse sup-                          Antimicrob. Agents Chemother. 49:3129â€“3135.
port daily oral dosing humans. figures constitute                  16.   Vries, H.,  J. Arendzen,  M. Kroon. 1973. interference                                                                                        macrolide antibiotics mitochondrial protein synthesis. Biochim. Bio- improvement previous half-life reports PDF inhib-                          phys. Acta 331:264â€“275.
itors (27). Oral bioavailabilities PDF-611 (LBK-611)                      17.   Dye, C. 2006. Global epidemiology tuberculosis. Lancet 367:938â€“940.
PDF-709 clear improvement reported                     18.   Dye, C., C. J. Watt, D. M. Bleed, S. M. Hosseini, M. C. Raviglione. 2005.
                                                                                       Evolution tuberculosis control prospects reducing tuberculosis PDF inhibitors class N-alkyl urea hydroxamic acids                        incidence, prevalence, deaths globally. JAMA 293:2767â€“2775.
(0.1 3.2 ) (27) BB-83698  v. application                  19.   Fantin, V. R., M. J. Berardi, L. Scorrano, S. J. Korsmeyer, P. Leder.
                                                                                       2002. novel mitochondriotoxic small molecule selectively inhibits
(52). total clearance levels moderate com-                           tumor cell growth. Cancer Cell 2:29â€“42.
pounds, e., 66 114 ml/min/kg PDF-611 (LBK-611)                     20.   Franzblau, S. G., R. S. Witzig, J. C. McLaughlin, P. Torres, G. Madico, 
PDF-709, respectively, lie range mouse liver                           Hernandez, M. T. Degnan, M. B. Cook, V. K. Quenzer, R. M. Ferguson,                                                                                        R. H. Gilman. 1998. Rapid, low-technology MIC determination clinical
blood flow (90 ml/min/kg).  group PDF inhibitors                          Mycobacterium tuberculosis isolates using microplate Alamar Blue potential developed new class                            assay. J. Clin. Microbiol. 36:362â€“366.
antituberculosis agent.                                                          21.   Giglione, C., T. Meinnel. 2001. Resistance anti-peptide deformylase
                                                                                       drugs. Expert Opin. Ther. Targets 5:415â€“418.
                                                                                 22.   Giglione, C.,  Serero, M. Pierre, B. Boisson, T. Meinnel. 2000. Iden-
                        ACKNOWLEDGMENTS                                                tification eukaryotic peptide deformylases reveals universality N-termi-
                                                                                       nal protein processing mechanisms. EMBO J. 19:5916â€“5929.
  thank Sabine Daugelat providing advice knockout pro-             23.   Gite, S., Y. Li, V. Ramesh, U. L. RajBhandary. 2000. Escherichia coli
cedure Marty Pavelka pYUB657. thank Brigitte Gicquel                    methionyl-tRNA formyltransferase: role amino acids conserved providing pJEM15, used overexpression studies.                           linker region C-terminal domain specific recognition                                                                                        initiator tRNA. Biochemistry 39:2218â€“2226.
                                                                                 24.   Gordon, J. J., B. K. Kelly, G.  Miller. 1962. Actinonin: antibiotic
                              REFERENCES
                                                                                       substance produced actinomycete. Nature 195:701â€“702.
1. Almassy, R. J., C.  Janson, C. C. Kan,  Hostomska. 1992. Structures   25.   Groche, D.,  Becker,  Schlichting, W. Kabsch, S. Schultz,  F.
   apo complexed Escherichia coli glycinamide ribonucleotide trans-             Wagner. 1998. Isolation crystallization functionally competent Esch-
   formylase. Proc. Natl. Acad. Sci. USA 89:6114â€“6118.                                 erichia coli peptide deformylase forms containing iron nickel 2. Apfel, C., D. W. Banner, D. Bur, M. Dietz, T. Hirata, C. Hubschwerlen, H.           active site. Biochem. Biophys. Res. Commun. 246:342â€“346.
 VOL. 50, 2006                                                                                 PDF INHIBITORS ANTIMYCOBACTERIALS                                    3673

26. Guillon, J.-M., Y. Mechulam, J.-M. Schmitter, S. Blanquet, G. Fayat.               Hydroxamic acids pharmacological agents. Curr. Med. Chem. 9:1631â€“
    1992. Disruption gene Met-tRNAfMetformyltransferase severely                1653.
    impairs growth Escherichia coli. J. Bacteriol. 174:4294â€“4301.                 45.   Nguyen, K. T., X. Hu, C. Colton, R. Chakrabarti, M. X. Zhu, D. Pei.
27. Hackbarth, C. J., D.  Chen, J. G. Lewis, K. Clark, J. B. Mangold, J.               2003. Characterization human peptide deformylase: implications     Cramer, P. S. Margolis, W. Wang, J. Koehn, C. Wu, S. Lopez, G. Withers III,            antibacterial drug design. Biochemistry 42:9952â€“9958.
    H. Gu, E. Dunn, R. Kulathila, S.-H. Pan, W. L. Porter, J. Jacobs, J. Trias,      46.   Nunn, P., B. Williams, K. Floyd, C. Dye, G. Elzinga, M. Raviglione.
    D. V. Patel, B. Weidmann, R. J. White,  Yuan. 2002. N-Alkyl urea                 2005. Tuberculosis control era HIV. Nat. Rev. Immunol. 5:819â€“826.
    hydroxamic acids new class peptide deformylase inhibitors           47.   Pavelka, M. S., Jr., W. R. Jacobs, Jr. 1999. Comparison construc-
    antibacterial activity. Antimicrob. Agents Chemother. 46:2752â€“2764.                    tion unmarked deletion mutations Mycobacterium smegmatis, Mycobac-
28. Klein, C., P. Chen, J. H. Arevalo, E.  Stura,  Marolewski, M. S. Warren,           terium bovis bacillus Calmette-GueÂ´rin, Mycobacterium tuberculosis
    S. J. Benkovic,   Wilson. 1995. structure-based drug design:           H37Rv allelic exchange. J. Bacteriol. 181:4780â€“4789.
    crystal structure multisubstrate adduct complex glycinamide ribonu-      48.   Penta, J. S., F. M. Johnson, J. T. Wachsman, W. C. Copeland. 2001.
    cleotide transformylase 1.96 resolution. J. Mol. Biol. 249:153â€“175.               Mitochondrial DNA human malignancy. Mutat. Res. 488:119â€“133.
29. Kremer, L. S., G. S. Besra. 2002. Current status future development      49.   Ragusa, S., S. Blanquet, T. Meinnel. 1998. Control peptide deformylase
    antitubercular chemotherapy. Expert Opin. Investig. Drugs 11:1033â€“1049.             activity metal cations. J. Mol. Biol. 280:515â€“523.
30. Kroon,  M., B. H. Dontje, M. Holtrop, C. Van den Bogert. 1984.         50.   Rajagopalan, P. T.,  Datta, D. Pei. 1997. Purification, characterization,
    mitochondrial genetic target chemotherapy: tetracyclines            inhibition peptide deformylase Escherichia coli. Biochemistry
    cytostatics. Cancer Lett. 25:33â€“40.                                                    36:13910â€“13918.
31. Kroon,  M., C. Van den Bogert. 1983. Antibacterial drugs         51.   Rajagopalan, P. T., D. Pei. 1998. Oxygen-mediated inactivation pep-
    interference biogenesis mitochondria animal human cells.            tide deformylase. J. Biol. Chem. 273:22305â€“22310.
    Pharm. Weekbl. Sci. 5:81â€“87.                                                     52.   Ramanathan-Girish, S., J. McColm, J. M. Clements, P. Taupin, S. Barrowcliffe,
32. Lee, M. D., C. Antczak, Y. Li, F. M. Sirotnak, W. G. Bornmann, D.                J. Hevizi, S. Safrin, C. Moore, G. Patou, H. Moser,  Gadd, U. Hoch, V. Jiang,
    Scheinberg. 2003. new human peptide deformylase inhibitable acti-                 D. Lofland, K. W. Johnson. 2004. Pharmacokinetics animals humans
    nonin. Biochem. Biophys. Res. Commun. 312:309â€“315.                                     class peptide deformylase inhibitor. Antimicrob. Agents Chemother.
33. Lee, M. D., Y.  M. J. Soskis, C. P. Borella, J. R. Gardner, P.  Hayes,           48:4835â€“4842.
    B. M. Dy, M. L. Heaney, M. R. Philips, W. G. Bornmann, F. M. Sirotnak,       53.   Ramesh, V., S. Gite, Y. Li, U. L. RajBhandary. 1997. Suppressor muta-
    D.  Scheinberg. 2004. Human mitochondrial peptide deformylase, new                 tions Escherichia coli methionyl-tRNA formyltransferase: role 16-
    anticancer target actinonin-based antibiotics. J. Clin. Investig. 114:1107â€“         amino acid insertion module initiator tRNA recognition. Proc. Natl. Acad.
    1116.                                                                                  Sci. USA 94:13524â€“13529.
34. Margolis, P., C. Hackbarth, S. Lopez, M. Maniar, W. Wang,  Yuan, R.            54.   Ramesh, V., S. Gite, U. L. RajBhandary. 1998. Functional interaction     White, J. Trias. 2001. Resistance Streptococcus pneumoniae                   arginine conserved sixteen amino acid insertion module Esch-
    deformylase inhibitors mutations defB. Antimicrob. Agents                 erichia coli methionyl-tRNA formyltransferase determinants formyl-
    Chemother. 45:2432â€“2435.                                                               ation initi